title: Clinical study with bromperidol, a new butyrophenone derivative.
abstract: 20 psychotic - predominantly schizophrenic - patients underwent treatment with the new butyrophenone derivative bromperidol for a period of 4 weeks; the drug was administered in the form of 1 mg tablets. The daily dose (initial dose: 1 mg; mean dose at the end of the trial: 4.47 mg) was always administered in one single dose. 19 patients finished the trial, and in 18 cases the therapeutic result was considered very good to good. These results were confirmed by statistical analysis. Nine patients exhibited mild to moderate extrapyramidal concomitant symptoms; no other side effects were observed. The results of detailed laboratory tests and evaluations of various quantitative and qualitative tolerability parameters were not indicative of toxic effects. The therapeutic value of this new substance will be demonstrated by a double-blind study.
mesh_terms: D000328:Adult; D001966:Bromine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006220:Haloperidol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D012559:Schizophrenia / Q000188:drug therapy*
chemical_list: D006220:Haloperidol; C006820:bromperidol; D001966:Bromine